With about a million people living with them Parkinson’s disease In the United States – and 90,000 new diagnoses every year – the race works for treatment.
Researchers at Memorial kettering Cancer Center (MSK) has announced progress in that front – they have developed a new treatment that uses stem cells to treat advanced tremors.
In the first stage experience, researchers used the donated stem cells (taken from the early stage fetuses) to create neurons (neurons) and planted them in the brains of 12 Parkinson’s patients, according to a MSK journalist.
As for a new drug in Parkinson, it is effective in clinical trials: “very encouraging”
Once the cells are injected, they produce dopamine, a hormone in the brain that helps in movement and coordination.
(One of the distinctive features of Parkinson’s company is low levels of dopamine, which causes the typical symptoms of tremors, hardening, balance problems and difficulty walking.)
About a million people live with Parkinson’s disease in the United States, with 90,000 new diagnoses every year. (Istock)
After 18 months, the cells that were injected were “held in the brain without any serious side effects,” the researchers said.
Based on MDS-UPDRS-the classification scale for the symptoms developed by the International Parkinson Association and movement disorder-the participants witnessed “noticeable improvements”, especially the group that received a The highest dose.
Patients in the high -dose group are 2.7 hours of “time” every day.
“Doctors of neurologists say that things usually get worse every year with this disease, which means that the result rises by a few points,” said the author of the study co -study, Lorenz, Director of the MSK Center in Stem Cell Biology.
“In our study, not only the result increased, but it decreased by more than 20 points in the high dose group.”
Researchers used the donated stem cells (taken from the early stage fetuses) to create neurons (neurons) and plant them in the brains of 12 Parkinson’s patients. (Istock)
On average, patients in the high-dose group have been more than 2.7 hours of “specified time”-which indicates periods of normal performance with minimal symptoms-and as a result they could be meaningful to their daily life.
Given the success of the first stage experience, the US Food and Drug Administration (FDA) granted researchers to go directly to a Stage 3 Clinical Experience In a much larger group of patients – about 100 people – which will occur in the first half of 2025.
The results were published in Nature.
The study reveals Parkinson’s cases worldwide by 2050
“The study showed that the development of specific neurons of human embryonic stem cells into the laboratory, then injected them into the brain of people with Parkinson’s disease, safe and returned with its promise k Possible future treatmentThe main author of the study, Vivian Tabar, head of the neurosurgery department at the Memorial Celing Cancer Center in New York City, told Fox News Digital.
“The results were rewarding, because this work is more than ten years in making.”
“A major step forward”
Dr. Mary Ann Bacon, medical director of the MS at the Holy Medical Center in Teaneck, New Jersey, said that the Barkinson’s treatment cells can provide potential not only to slow the disability, but also to stop progress and achieve improvement in the motor function.
“Although there is a risk in suppressing the necessary immunity before Stem cell transplant The same procedure, will be a big step forward in replacing the dopamine neurons lost in this disease, ”said Bacon, who did not participate in the study, told Fox News Digital.
Click here to get the Fox News app
Levodopa, currently the treatment of the first line of Parkinson’s company, is limited to the fact that patients need larger dose amounts over time, according to Picone- “regulating periods of hardness or movement defects (more difficult muscle movements).”
After 18 months, the cells that were injected were “held in the brain without any serious side effects,” the researchers said. (Istock)
Dr. Ann Murray, Director of Movement Disorders at the Woweller Institute for Neurology in Western Virginia, referred to the study as “”IncredibleFor Parkinson’s patients.
“Although the goal of this research project is to ensure safety, getting this major clinical improvement in UPDRS is completely pioneering,” Murray told Fox News Digital. (You also did not participate in the study.)
Click here to register in our health newsletter
“This is the first step only in obtaining this type of approved treatment for patients with Parkinson’s disease, but this is an amazing first step for the potential benefits from Stem cell brain treatment“
Possible restrictions
Tabar indicated that there are some restrictions related to the study.
She said: “This is a small study designed to show safety-it is important to conduct a greater control that is well controlled to prove that the treatment already works, otherwise it is indicated as a study of stage 3.”
“This is an amazing first step for the potential benefits of the treatment of stem cells.”
These early results, however, “suggest a strong promise.”
“I think we can finally say that the stem cells, when they are derived and discriminatory properly, pledged a great promise to repair the brain in Parkinson’s and perhaps in Other conditions One day, Tabar said.
For more health articles, please visit www.foxnews.com/health
MSK cell therapy was developed and was licensed to treat Bluerock in Massachusetts, which funded the study.
https://static.foxnews.com/foxnews.com/content/uploads/2025/04/woman-holding-coffee-mug.jpg
Source link